Cancer Communications
indexed by SCI
BMC

doi: 10.5732/cjc.011.10236
Platelet-derived growth factor receptor alpha in glioma: a bad seed
Kun-Wei Liu, Bo Hu, Shi-Yuan Cheng
University of Pittsburgh Cancer Institute; Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA. hub@upmc.edu,chengs@upmc.edu
[Abstract] Recent collaborative, large-scale genomic profiling of the most common and aggressive brain tumor glioblastoma multiforme(GBM) has significantly advanced our understanding of this disease. The gene encoding platelet-derived growth factor receptor alpha(PDGFRα) was identified as the third of the top 11 amplified genes in clinical GBM specimens. The important roles of PDGFRα signaling during normal brain development also implicate the possible pathologic consequences of PDGFRα over-activation in glioma. Although the initial clinical trials using PDGFR kinase inhibitors have been predominantly disappointing, diagnostic and treatment modalities involving genomic profiling and personalized medicine are expected to improve the therapy targeting PDGFRα signaling. In this review, we discuss the roles of PDGFRαsignaling during development of the normal central nervous system(CNS) and in pathologic conditions such as malignant glioma. We further compare various animal models of PDGF-induced gliomagenesis and their potential as a novel platform of pre-clinical drug testing. We then summarize our recent publication and how these findings will likely impact treatments for gliomas driven by PDGFRα overexpression. A better understanding of PDGFRα signaling in glioma and their microenvironment, through the use of human or mouse models, is necessary to design a more effective therapeutic strategy against gliomas harboring the aberrant PDGFRα signaling.
Chinese Journal of Cancer 2011, Volume: 30, Issue 9, Page: 590-602
[ PDF Full-text ]
[Google Scholar]


Cite this article

Kun-Wei Liu, Bo Hu, Shi-Yuan Cheng. Platelet-derived growth factor receptor alpha in glioma: a bad seed. Chin J Cancer. 2011, 30(9):590-602. doi:10.5732/cjc.011.10236


Export citations

EndNote


SHARE THIS ARTICLE


Your Comments

  

 


Comments:


CJC Wechat 微信公众号


 

Editorial Manager


CC adopts ScholarOne Manuscripts to manage its submissions from Nov.1, 2019

 Submission Guidelines  

 

Reference style for  

 EndNote,
 Reference Manager



Editorial Manager


 

Year:

 

Month:

Advanced search

Subscription


CC is now published by Wiley

© Cancer Communications

651 Dongfeng Road East, Guangzhou 510060, P. R. China